In this month’s edition, we highlight the impact of Brexit uncertainty on the life sciences sector, the slowdown in IPO activity in the US and Europe as well as the early positive indicators in US biotech owing to policy changes under the Trump administration. We also summarise the most important deals, before providing an at-a-glance overview of financial performance and news from sector companies.

Click here to download the report >>